Skip to main content
. 2020 May 11;2020(5):CD003689. doi: 10.1002/14651858.CD003689.pub4
# Query
S1 (MH“CerebrovascularDisorders”)OR (MH“Basal Ganglia CerebrovascularDisease+”) OR (MH“Carotid ArteryDiseases+”)
OR (MH “Cerebral Ischemia+”) OR (MH “Cerebral Vasospasm”) OR (MH “Intracranial Arterial Diseases+”) OR (MH
“Intracranial Embolism and Thrombosis”) OR (MH “Intracranial Hemorrhage+”) OR (MH “Stroke”) OR (MH “Vertebral
Artery Dissections”)
S2 (MH “Stroke Patients”) OR (MH “Stroke Units”)
S3 TI (stroke or poststroke or post‐stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex or SAH) or AB (stroke
or poststroke or post‐stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex or SAH)
S4 TI (brain* or cerebr* or cerebell* or intracran* or intracerebral ) or AB ( brain* or cerebr* or cerebell* or intracran* or
intracerebral)
S5 TI (ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus*) or AB (ischemi* or ischaemi* or infarct* or thrombo*
or emboli* or occlus*)
S6 S4 and S5
S7 TI (brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) or AB (brain* or cerebr* or cerebell* or
intracerebral or intracranial or subarachnoid)
S8 TI (haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed*) or AB (haemorrhage* or hemorrhage* or
haematoma* or hematoma* or bleed*)
S9 S7 and S8
S10 (MH “Hemiplegia”)
S11 TI (hemipleg* or hemipar* or paresis or paretic) or AB (hemipleg* or hemipar* or paresis or paretic)
S12 S1 or S2 or S3 or S6 or S9 or S10 or S11
S13 (MH “Depression”) OR (MH “Depression, Reactive”) OR (MH “Dysthymic Disorder”)
S14 (MH “Antidepressive Agents+”)
S15 TI (depress* or dysthymi*or dysphor*or antidepress*or anti‐depress* ) OR AB ( depress* or dysthymi*or dysphor*or antidepress*
or anti‐depress*)
S16 S13 OR S14 OR S15
S17 (MH "Randomized Controlled Trials") or (MH “Random Assignment”) or (MH “Random Sample+”)
S18 (MH "Clinical Trials") or (MH “Intervention Trials”) or (MH “Therapeutic Trials”)
S19 (MH "Double‐blind Studies") or (MH “Single‐Blind Studies”) or (MH “Triple‐Blind Studies”)
S20 (MH "Control (Research)") or (MH “Control Group”) or (MH “Placebos”) or (MH “Placebo Effect”)
S21 (MH “Crossover Design”) OR (MH “Quasi‐Experimental Studies”)
S22 PT (clinical trial or randomized controlled trial)
S23 TI (random* or RCT or RCTs) or AB (random* or RCT or RCTs)
S24 TI (controlled N5 (trial* or stud*)) or AB (controlled N5 (trial* or stud*))
S25 TI (clinical* N5 trial*) or AB (clinical* N5 trial*)
S26 TI ((control or treatment or experiment* or intervention) N5 (group* or subject* or patient*)) or AB ((control or treatment
or experiment* or intervention) N5 (group* or subject* or patient*))
S27 TI ((control or experiment* or conservative) N5 (treatment or therapy or procedure ormanage*)) or AB((control or experiment*
or conservative) N5 (treatment or therapy or procedure or manage*))
S28 TI ((singl* or doubl* or tripl* or trebl*) N5 (blind* or mask*)) or AB ((singl* or doubl* or tripl* or trebl*) N5 (blind* or
mask*))
S29 TI (cross‐over or cross over or crossover) or AB (cross‐over or cross over or crossover)
S30 TI (placebo* or sham) or AB (placebo* or sham)
S31 TI trial
S32 TI (assign* or allocat*) or AB (assign* or allocat*)
S33 TI controls or AB controls
S34 TI (quasi‐random* or quasi random* or pseudo‐random* or pseudo random*) or AB (quasi‐random* or quasi random* or
pseudo‐random* or pseudo random*)
S35 S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR
S31 OR S32 OR S33 OR S34 S36.S12 AND S16 AND S35
S36 S6 AND S16 AND S35